Gain more flexibility with outpatient administration
Outpatient administration of VYXEOS was used for some patients in the Phase 3 study, and multiple institutions have evaluated its use in real-world practice.1-4,a
Administration Schedule
Outpatient Strategies
Real-world strategies for outpatient administration of VYXEOS5
aMost patients in the Phase 3 study received induction in an inpatient setting.4
Patient Assessment
Patient assessment should happen before, during, and after treatment5
Supportive care
Ensure timely access to supportive care
Supportive care may include5
Blood and platelet transfusion support
- Patients may require frequent transfusions during outpatient care
Prophylactic antimicrobial implementation
- Prophylaxis with antibacterials, antifungals, and antivirals may be recommended if a patient is considered at high risk for infection
Wellness support
- Supportive care, such as hydration, antiemetic support, and correction of electrolyte imbalances, are vital to patient care
Additional considerations for outpatient treatment
- Inpatient access allows for unplanned admission due to urgent adverse reactions or if a patient requires frequent monitoring and/or transfusion support6
- Some institutions may prefer preplanned admission to monitor patients more closely2
- A patient who does not experience any major complications may be able to complete all treatment in an outpatient setting5
Patient Setting
Institutions have evaluated administering VYXEOS
Institutions have evaluated administering VYXEOS
in the outpatient setting2,3
In 2 small, postapproval, single-institution studies, more than half of patients initiated VYXEOS induction in the outpatient setting.
In a small, single-center pilot study by Kubal et al, 22 patients received a full induction course of VYXEOS
- Patients were evaluated each day with CBC, CMP, and uric acid and phosphorus measures
- Planned admission occurred on Day 6 for continued care
- 64% (n=14; median age 69 years) received induction in an IPOP setting, and 93% of those patients (n=13) were admitted for continued care on Day 6, as planned
- One patient was admitted on Day 2 of induction
In a small, single-center pilot study by Deutsch et al, 12 patients received a full induction course of VYXEOS
- Patients were monitored at least every other day until count recovery and admitted for continued care if complications occurred
- 58% (n=7; median age 72 years) received induction in an IPOP setting
- Of these 7 patients, 86% (n=6) were eventually admitted for continued care; all admissions were due to infection complications
- One patient was admitted prior to completing the third induction dose
These 2 studies assessed the feasibility of patients receiving VYXEOS induction in the inpatient/outpatient setting2,3
Exclusion criteria for outpatient administration were similar across these 2
studies2,3
Treatment in an IPOP setting enables appropriate patients to receive induction in an outpatient setting, with inpatient admission scheduled as needed for continued monitoring and care or for treatment for adverse reactions.2,3
ANC=absolute neutrophil count; CBC=complete blood count; CMP=comprehensive metabolic panel; ECOG PS=Eastern Cooperative Oncology Group Performance Status; IPOP=inpatient/outpatient; LDH=lactate dehydrogenase; TLS=tumor lysis syndrome.
bANC >0.5 x 109/L.5
cThe admission stay typically lasts an average of 30 days (ranging between 25 and 50 days).5
dFrequency of assessment may be modified based on patient need.5
Dosing Schedule
Treatment with VYXEOS gives your patients additional flexibility between induction and consolidation cycles.7
more
Preparation & Administration
VYXEOS is prepared for infusion through straightforward steps.7 View helpful guides on how to prepare and administer VYXEOS.
more
